Definium Therapeutics (DFTX) Other Accumulated Expenses (2020 - 2026)
Definium Therapeutics (DFTX) reported Other Accumulated Expenses of $604000.0 for Q1 2026, up 131.42% year-over-year from $261000.0 in Q1 2025, and up 18.43% quarter-over-quarter from $510000.0 in Q4 2025.
Definium Therapeutics (DFTX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 7 years of Other Accumulated Expenses data on file, last reported at $604000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $604000.0, up 131.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $604000.0 (up 131.42% YoY), and the FY2025 annual result was $510000.0, up 83.45% from the prior year.
- Other Accumulated Expenses grew to $604000.0 in Q1 2026 per DFTX's latest filing, from $510000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $685000.0 in Q2 2024 and troughed at $45000.0 in Q1 2022.
- A 5-year average of $312764.7 and a median of $291000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses surged 2300.0% in 2022, then slumped 60.53% in 2023.
- A 5-year view of Other Accumulated Expenses shows it stood at $72000.0 in 2022, then surged by 401.39% to $361000.0 in 2023, then retreated by 22.99% to $278000.0 in 2024, then surged by 83.45% to $510000.0 in 2025, then rose by 18.43% to $604000.0 in 2026.
- Business Quant data shows DFTX's Other Accumulated Expenses at $604000.0 in Q1 2026, $510000.0 in Q4 2025, and $498000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 604,000.00 |
| Dec 31, 2025 | 510,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 261,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Sep 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 685,000.00 |
| Mar 31, 2024 | 291,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Sep 30, 2023 | 436,000.00 |
| Jun 30, 2023 | 90,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Dec 31, 2022 | 72,000.00 |
| Sep 30, 2022 | 93,000.00 |
| Jun 30, 2022 | 228,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 186,000.00 |